Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q4 FY25 results · Jan–Mar 2025
Aarti Drugs reported revenue from operations of ₹676.76 crore (up 9.2% from Q4 FY24) and net profit of ₹62.77 crore (up 32.7% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 676.76 | 619.99 | +9.2% | 556.60 | +21.6% |
| Other income | 1.87 | 1.08 | +73.1% | 11.90 | −84.3% |
| Total income | 678.63 | 621.07 | +9.3% | 568.50 | +19.4% |
| Profit before tax | 71.15 | 64.18 | +10.9% | 50.76 | +40.2% |
| Net profit for the period | 62.77 | 47.31 | +32.7% | 37.09 | +69.2% |
| Attributable to shareholders of the company | 62.86 | 47.37 | +32.7% | 37.05 | +69.7% |
| EPS, basic (₹) | 6.88 | 5.15 | +33.6% | 4.06 | +69.5% |
| Net margin (%) | 9.3 | 7.6 | 6.7 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 622.96 | 559.53 | +11.3% | 514.54 | +21.1% |
| Other income | 1.71 | 1.11 | +54.1% | 11.37 | −85.0% |
| Total income | 624.67 | 560.64 | +11.4% | 525.91 | +18.8% |
| Profit before tax | 70.67 | 49.74 | +42.1% | 52.03 | +35.8% |
| Net profit for the period | 61.48 | 36.14 | +70.1% | 38.53 | +59.6% |
| EPS, basic (₹) | 6.74 | 3.93 | +71.5% | 4.22 | +59.7% |
| Net margin (%) | 9.9 | 6.5 | 7.5 |
Consolidated
- Filed with BSE
- 06 May 2025, 20:47 IST
- Board meeting
- 06 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 May 2025, 20:47 IST
- Board meeting
- 06 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE